Zoetis Inc. (NYSE:ZTS) Shares Purchased by Legacy Capital Wealth Partners LLC

Legacy Capital Wealth Partners LLC boosted its stake in shares of Zoetis Inc. (NYSE:ZTS) by 7.5% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,363 shares of the company’s stock after acquiring an additional 95 shares during the quarter. Legacy Capital Wealth Partners LLC’s holdings in Zoetis were worth $269,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently modified their holdings of ZTS. Blue Bell Private Wealth Management LLC increased its stake in Zoetis by 222.5% in the 4th quarter. Blue Bell Private Wealth Management LLC now owns 129 shares of the company’s stock valued at $25,000 after buying an additional 89 shares during the period. Independence Bank of Kentucky raised its holdings in Zoetis by 371.4% during the fourth quarter. Independence Bank of Kentucky now owns 165 shares of the company’s stock worth $33,000 after purchasing an additional 130 shares in the last quarter. Ramirez Asset Management Inc. acquired a new stake in Zoetis in the third quarter valued at about $35,000. First Financial Corp IN boosted its holdings in Zoetis by 57.2% in the 4th quarter. First Financial Corp IN now owns 217 shares of the company’s stock valued at $43,000 after purchasing an additional 79 shares in the last quarter. Finally, FinTrust Capital Advisors LLC increased its position in Zoetis by 42.1% during the 3rd quarter. FinTrust Capital Advisors LLC now owns 260 shares of the company’s stock worth $45,000 after purchasing an additional 77 shares during the period. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Zoetis Price Performance

Shares of NYSE:ZTS opened at $159.78 on Tuesday. The company has a debt-to-equity ratio of 1.32, a quick ratio of 2.00 and a current ratio of 3.36. The business’s fifty day moving average price is $171.21 and its two-hundred day moving average price is $179.23. The stock has a market cap of $73.08 billion, a PE ratio of 31.51, a price-to-earnings-growth ratio of 2.42 and a beta of 0.85. Zoetis Inc. has a one year low of $144.80 and a one year high of $201.92.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Tuesday, February 13th. The company reported $1.24 EPS for the quarter, missing analysts’ consensus estimates of $1.32 by ($0.08). The company had revenue of $2.21 billion for the quarter, compared to analysts’ expectations of $2.19 billion. Zoetis had a return on equity of 51.25% and a net margin of 27.43%. The company’s revenue for the quarter was up 8.5% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.15 EPS. On average, analysts forecast that Zoetis Inc. will post 5.79 EPS for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 4th. Stockholders of record on Friday, April 19th will be issued a dividend of $0.432 per share. This represents a $1.73 annualized dividend and a dividend yield of 1.08%. The ex-dividend date of this dividend is Thursday, April 18th. Zoetis’s dividend payout ratio (DPR) is 34.12%.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the company. The Goldman Sachs Group upped their price objective on Zoetis from $190.00 to $226.00 and gave the stock a “buy” rating in a report on Wednesday, January 17th. Barclays cut their price target on shares of Zoetis from $260.00 to $230.00 and set an “overweight” rating for the company in a report on Tuesday, April 23rd. StockNews.com lowered shares of Zoetis from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 20th. Piper Sandler reiterated an “overweight” rating and set a $195.00 price target (down from $220.00) on shares of Zoetis in a research report on Tuesday, April 16th. Finally, Stifel Nicolaus lowered their price target on Zoetis from $215.00 to $195.00 and set a “buy” rating on the stock in a report on Tuesday, April 2nd. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Zoetis presently has a consensus rating of “Buy” and a consensus price target of $218.00.

Insider Activity

In other Zoetis news, EVP Roxanne Lagano sold 363 shares of the firm’s stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $197.74, for a total value of $71,779.62. Following the sale, the executive vice president now directly owns 20,417 shares of the company’s stock, valued at approximately $4,037,257.58. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders sold a total of 2,209 shares of company stock valued at $371,293 over the last quarter. Company insiders own 0.16% of the company’s stock.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.